Lytix Biopharma AS (OSL:LYTIX) Other Current Receivables: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
31 GF Score
Price kr8.50
GF Value kr0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Other Current Receivables?

Lytix Biopharma AS OSL:LYTIX +0.95% 31 Other Current Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSL:LYTIX with a GF Score™ of 31/100 and a GF Value™ of kr0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Lytix Biopharma AS's Other Current Receivables for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Lytix Biopharma AS's annual Other Current Receivables increased from Dec. 2023 (kr11.77 Mil) to Dec. 2024 (kr11.78 Mil) but then declined from Dec. 2024 (kr11.78 Mil) to Dec. 2025 (kr5.38 Mil).

Lytix Biopharma AS Other Current Receivables Related Terms

Lytix Biopharma AS Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Other Current Receivables Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 4.82 5.50 11.77 11.78 5.38

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 5.38 0.00
OSL:LYTIX
31GF Score
Lytix Biopharma AS OSL:LYTIX
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr0.00 Mil mean?
Lytix Biopharma AS (OSL:LYTIX) has a Other Current Receivables of kr0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Other Current Receivables too high?
Lytix Biopharma AS's current Other Current Receivables is kr0.00 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Other Current Receivables compare to VRTX and REGN?
Lytix Biopharma AS's Other Current Receivables of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Other Current Receivables is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr8.50 — trading 4900% above its estimated fair value. The current Other Current Receivables is kr0.00 Mil. Lytix Biopharma AS's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Other Current Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr8.50 is trading 4900% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Other Current Receivables: kr0.00 Mil
  • GF Value™: kr0.17 vs. price of kr8.50 (4900% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
31GF Score

Get the complete analysis for OSL:LYTIX

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.50
Price
kr0.17
GF Value